secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0000950170-24-088200
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M
--------------------------------------------------------------------------------

- Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.
- Option for exclusive worldwide license; upfront and option exercise fees up to $6.5M.
- Targets B7H3/PTK7 co-expression in lung, colorectal, head and neck cancers with double-digit prevalence.
- Development candidate nomination targeted for H2 2024; potential combo with DDR pipeline including IDE161 (PARG).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024088200/0000950170-24-088200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024088200/idya-20240730.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer